Eevia Health Plc ("Eevia" or "The Company") announces that the last day of trading in Eevia TO 1 will be 2025-08-26
Eevia issued TO 1 warrants as part of the offering in the Rights Issue in August 2024. Eevia now announces that the last day of trading in Eevia TO 1 will be August 26, 2025 (2025-08-26).
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga mushroom, and pine bark, are wild harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden (Ticker EEVIA).
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.